menu
    • menu

    Company profile for Vaximm AG

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens. The Company’s lead product candidate, oral VXM01, currently in clinical trials, activates kill...
    VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens. The Company’s lead product candidate, oral VXM01, currently in clinical trials, activates killer T-cells targeting tumor vasculature and certain immune-suppressive cells and causes increased inflammation in solid tumors.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vaximm AGSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Hochbergerstrasse 60c CH – 4057 Basel
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vaximm.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vaximm-ag
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/hashtag/vaximm

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vaximm AG Enters Term With BCM Europe for VXM01 License
    Vaximm AG Enters Term With BCM Europe for VXM01 License

    21 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vaximm-ag-an-osr-company-enters-term-sheet-with-bcm-europe-for-potential-vxm01-license-with-20m-upfront-and-up-to-815m-in-milestones-302623234.html

    PR NEWSWIRE
    21 Nov 2025
    Share Share
    OSR Holdings Names Dr. Andreas Niethammer of CEO Of Vaximm AG
    OSR Holdings Names Dr. Andreas Niethammer of CEO Of Vaximm AG

    14 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/osr-holdings-appoints-scientific-co-founder-dr-andreas-niethammer-as-chief-executive-officer-of-vaximm-ag-to-lead-next-phase-of-immuno-oncology-expansion-302615840.html

    PR NEWSWIRE
    14 Nov 2025
    Share Share
    Vaximm AG Announces Phase 2a Trial Results for Glioblastoma
    Vaximm AG Announces Phase 2a Trial Results for Glioblastoma

    26 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vaximm-ag-an-osr-company-announces-results-from-phase-2a-trial-of-vxm01-and-avelumab-combination-therapy-in-glioblastoma-302411928.html

    PR NEWSWIRE
    26 Mar 2025
    Share Share
    NEC OncoImmunity acquires Vaximm's neoantigen vaccine development assets
    NEC OncoImmunity acquires Vaximm's neoantigen vaccine development assets

    09 Mar 2022

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=146291&sid=2

    PHARMABIZ
    09 Mar 2022
    Share Share
    NEC, VAXIMM to advance personalized neoantigen cancer vaccines
    NEC, VAXIMM to advance personalized neoantigen cancer vaccines

    15 Nov 2019

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/37/14890/nec-vaximm-to-advance-personalized-neoantigen-cancer-vaccines.html

    BIOSPECTRUM ASIA
    15 Nov 2019
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search